申请人:THE SCRIPPS RESEARCH INSTITUTE
                            
                            
                                公开号:EP2428226A1
                            
                            
                                公开(公告)日:2012-03-14
                            
                            
The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.
                            本发明提供了
抗体靶向化合物,通过共价或非共价方式将靶向制剂与
抗体的结合位点连接,对
抗体的特异性进行了重新编程。通过这种方法,共价修饰的
抗体具有了靶向制剂的结合特异性。化合物的
生物活性可由靶向药剂或单独的
生物药剂提供。本发明化合物有多种用途。